secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptiNose, Inc. (—)
CIK:        0001494650
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001494650-24-000042
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Optinose reports Q1 XHANCE revenue $14.9M (+26% YoY); sees peak >$300M
----------------------------------------------------------------------

- Q1 2024 XHANCE net revenue $14.9M, up ~26% vs Q1 2023.
- FDA approved XHANCE as first drug treatment for chronic sinusitis without nasal polyps.
- Expects peak XHANCE net revenue >$300M; positive GAAP ops income by FY2025.
- Leveraging 75 sales territories to target 3M patients; limited incremental spend.
- Plans to use specialty pharmacy hub to improve prescription fill and reimbursement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1494650/000149465024000042/0001494650-24-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1494650/000149465024000042/optn-20240425.htm
  HTML page:      https://secwatch.observer/filing/0001494650-24-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer